Inside the Workday of a Regulatory Affairs Specialist

Morning: Prioritization, Planning, and Health Authority Monitoring

Regulatory affairs professionals start their day by reviewing email correspondence from global health authorities such as the FDA, EMA, and local regulators. Updates may include feedback on active submissions, questions (queries or deficiencies), or changes in regulatory guidelines.

Typical first-hour tasks include:

• ✅ Reviewing submission tracker updates from the global team
• ✅ Checking the status of ongoing eCTD publishing activities
• ✅ Assessing if internal change controls have any regulatory impact
• ✅ Reading industry alerts on new requirements (e.g., updates to EU-CTR)

Professionals often align with global teams across time zones to review upcoming deadlines for CTAs (Clinical Trial Applications), INDs, NDAs, or post-approval variations.

Mid-Morning: Cross-Functional Meetings and Submission Preparation

By mid-morning, RA staff typically participate in project team meetings. These can include:

• ✅ CMC (Chemistry, Manufacturing and Controls) updates on batch release status
• ✅ Clinical team reports on patient recruitment for trial applications
• ✅ Safety team discussions for Periodic Safety Update Reports (PSURs)

The RA professional gathers information relevant for submission dossiers and uses Regulatory Information Management Systems (RIMS) to track documents.

A case study example: During a pre-submission meeting with the EMA for a biosimilar application, a regulatory associate was responsible for compiling the Product Quality Review data and validating the Summary of Product Characteristics (SmPC) to ensure it matched the reference product.

Late Morning: Dossier Compilation and Document QC

Late mornings are usually dedicated to hands-on work. This includes:

• ✅ Performing quality control (QC) on clinical study reports before submission
• ✅ Reviewing labeling content and translations
• ✅ Cross-checking Module 3 documents for consistency with the latest CMC changes
• ✅ Coordinating with publishing teams to finalize the eCTD structure

Tools commonly used include Documentum, Veeva Vault, Lorenz docuBridge, and internal LIMS or RIMS platforms. Accuracy is paramount because even minor errors can lead to submission rejections or delays.

Afternoon: Responding to Agency Queries and Preparing Briefing Documents

Post-lunch hours are reserved for higher focus tasks. This is the time when RA professionals:

• ✅ Draft response letters to agency queries with cross-functional input
• ✅ Prepare briefing packages for pre-submission meetings
• ✅ Work with medical writers to draft Clinical Overviews and Nonclinical Summaries
• ✅ Review and update global submission plans across markets

Example: In a US FDA Type C meeting for a rare disease drug, the regulatory lead compiled a list of targeted questions, scientific justifications, and proposed study endpoints to drive strategic discussion.

Evening: Compliance Reviews, Archive Tasks, and Documentation

Before wrapping up, regulatory professionals ensure that all activities of the day are documented and archived as per SOPs. Key end-of-day tasks include:

• ✅ Updating internal regulatory trackers
• ✅ Filing correspondence and submission components into electronic archives
• ✅ Logging decisions or feedback into CAPA or risk registers (if applicable)
• ✅ Planning task lists for the following day

RA staff must also ensure their documentation is inspection-ready. This includes audit trails, version control, and electronic signatures. As outlined on PharmaSOP.in, a good RA professional adheres to both system- and document-level compliance protocols.

Real-Life Case Study: Accelerated NDA Filing with Team Synergy

At a leading Indian biotech firm, an RA team was tasked with filing an NDA within a shortened 4-month timeline. Through seamless collaboration with clinical, CMC, and safety functions, and strategic communication with the FDA, the submission was not only filed on time but received approval in the first review cycle. The key factors? Strong project planning, proactive query mitigation, and deep regulatory knowledge—all orchestrated through a disciplined daily routine.

Conclusion

A regulatory professional’s day is a structured blend of strategic planning, document management, stakeholder coordination, and agency interfacing. Success in this role requires not just technical knowledge but time management, attention to detail, and strong communication skills. Each hour of the day contributes to bringing safe and effective therapies closer to patients through compliance and collaboration.

References:

• European Medicines Agency – Regulatory Guidelines
• FDA – Drug Submission Resources
• ICH Quality Guidelines

Navigating the EMA’s Centralised Marketing Authorisation Procedure

The Centralised Marketing Authorisation Procedure is the key pathway for obtaining drug approval across the European Union (EU) through a single application submitted to the European Medicines Agency (EMA). This regulatory route is essential for companies aiming to commercialize their medicinal products across all EU member states, as well as Iceland, Liechtenstein, and Norway. This comprehensive guide outlines the eligibility criteria, application components, submission process, and regulatory timelines to help applicants successfully navigate the centralised procedure.

What is the Centralised Procedure?

The Centralised Marketing Authorisation Procedure allows sponsors to submit one application, undergo a single scientific evaluation by the EMA’s Committee for Medicinal Products for Human Use (CHMP), and receive a binding decision from the European Commission (EC) valid in all EU and EEA countries. This harmonised process ensures consistency in drug approval, especially for innovative and high-impact medicinal products.

Primary Benefits of the Centralised Procedure:

• One application, one evaluation, and one marketing authorisation valid throughout the EU/EEA
• Access to all EU countries simultaneously
• Accelerated review options for priority products
• Scientific support through pre-submission meetings with EMA

Eligibility Criteria for Centralised Authorisation:

The centralised procedure is mandatory or optional based on product type:

Mandatory for:

• Biotechnological medicinal products
• Advanced therapy medicinal products (ATMPs)
• Orphan medicinal products
• New active substances for cancer, neurodegenerative disorders, diabetes, auto-immune diseases, etc.
• Medicines for HIV/AIDS, viral hepatitis, and rare diseases

Optional for:

• Products offering significant therapeutic, scientific, or technical innovation
• Medicines in the interest of public health at EU level

Step-by-Step Application Process:

1. Eligibility Request (Optional but Recommended): Sponsors can request a confirmation from EMA on whether their product qualifies for centralised procedure.
2. Pre-submission Meetings: Schedule early meetings with EMA 6-7 months before submission to clarify regulatory expectations, dossier requirements, and procedural timelines.
3. Submission of MAA (Marketing Authorisation Application): Use the electronic Common Technical Document (eCTD) format via the EU Submission Portal.
4. Validation Phase (0–30 days): EMA checks the completeness and correctness of the application.
5. Scientific Evaluation (Day 1–210): Conducted in two phases by CHMP, with the possibility of clock-stops for sponsor responses.
6. Final Opinion and EC Decision (Day 277–300): EMA submits its opinion to the EC for legally binding decision across the EU.

Content of the Marketing Authorisation Application:

The application must include:

• Module 1: Regional administrative information, product information, and labeling
• Module 2: Summaries of quality, non-clinical, and clinical data
• Module 3: Quality data including manufacturing and control
• Module 4: Non-clinical study reports
• Module 5: Clinical study reports (efficacy and safety)

Scientific Committees Involved:

• CHMP (Committee for Medicinal Products for Human Use): Core committee responsible for evaluating human medicines
• PRAC (Pharmacovigilance Risk Assessment Committee): Assesses safety and risk-benefit balance
• CAT (Committee for Advanced Therapies): Evaluates ATMPs
• COMP (Committee for Orphan Medicinal Products): Recommends orphan drug designation

Timelines and Clock-Stops:

The standard evaluation timeframe is 210 active days, with additional clock-stop periods for sponsor responses. The overall process from submission to European Commission decision can take up to 12 months, or faster under accelerated assessment (150 days) for products of major public health interest.

Labelling and Translations:

Product information (SmPC, labelling, and package leaflet) must be submitted in all 24 official EU languages before authorisation can be granted. EMA coordinates translation review and quality checks across member states.

Post-Authorisation Commitments:

• Risk Management Plans (RMP): Mandatory for most new products to monitor post-market safety
• Post-authorisation Safety Studies (PASS): To evaluate safety in real-world settings
• Renewals: After 5 years, the authorisation must be renewed for indefinite validity
• Variations: Any post-approval change must be submitted through variation procedures (Type IA, IB, II)

Special Considerations for SMEs and Orphan Drugs:

The EMA provides regulatory, administrative, and financial support to small and medium-sized enterprises (SMEs). Orphan drugs benefit from protocol assistance, fee reductions, and 10 years of market exclusivity.

Best Practices for a Successful Application:

1. Initiate early communication with EMA and request scientific advice if necessary.
2. Ensure dossier quality, completeness, and adherence to current guidelines and templates.
3. Utilize the EMA Pre-Authorisation Procedural Advice Manual for step-by-step submission rules.
4. Prepare for GxP inspections during validation and review phases.
5. Align clinical study design with EMA guidelines and CHMP expectations.

Harmonization with Global Regulations:

The EMA’s centralised procedure aligns closely with global regulatory frameworks such as those of the USFDA and CDSCO. This allows multinational companies to prepare core dossiers usable across multiple regulatory agencies.

Conclusion:

The EMA’s Centralised Marketing Authorisation Procedure offers a streamlined route to pan-European approval, critical for the launch of innovative medicines. Understanding the eligibility rules, dossier structure, regulatory interactions, and post-approval commitments is essential for regulatory success. For ongoing updates and document alignment, platforms like Stability Studies and reference to Pharma GMP compliance tools provide much-needed guidance. In-house teams can further benefit from structured documentation available at Pharma SOPs for optimal readiness during EMA review processes.